Brief: Theratechnologies Receives January 2024 PDUFA Goal Date For Tesamorelin F8 Formulation Sbla
Oct 4 (Reuters) - Theratechnologies Inc TH.TO :
* THERATECHNOLOGIES RECEIVES JANUARY 2024 PDUFA GOAL DATE
FOR
TESAMORELIN F8 FORMULATION SBLA
* THERATECHNOLOGIES INC - FDA ASSIGNED PDUFA GOAL DATE OF
JANUARY
22, 2024 TO CO'S SBLA OF F8 FORMULATION OF TESAMORELIN
Source text for Eikon: ID:nGNX4x45j3
Further company coverage: TH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theratechnologies
See all newsBrief: Theratechnologies Receives Final Court Approval On To Be Acquired By Future Pak
Brief: Theratechnologies Inc - Iss And Glass Lewis Recommend Voting 'For' Future Pak Arrangement
Canadian drugmaker Theratechnologies beats Q2 revenue estimates on strong demand
Brief: Theratechnologies Enters Into Definitive Agreement To Be Acquired By Cb Biotechnology, An Affiliate Of Future Pak
Brief: Theratechnologies Inc Decided To Further Evaluate Potential Sale Of Company Through An Open And Non-Exclusive Process